Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Current Leases (2016 - 2025)

Ironwood Pharmaceuticals' Current Leases history spans 16 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Current Leases rose 1.98% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 1.98%, while the annual FY2025 figure was $3.3 million, 1.98% up from the prior year.
  • Current Leases for Q4 2025 was $3.3 million at Ironwood Pharmaceuticals, roughly flat from $3.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.3 million in Q4 2025 and bottomed at $3.0 million in Q3 2022.
  • The 5-year median for Current Leases is $3.1 million (2021), against an average of $3.1 million.
  • The largest annual shift saw Current Leases soared 67.59% in 2021 before it decreased 3.39% in 2022.
  • A 5-year view of Current Leases shows it stood at $3.1 million in 2021, then dropped by 1.98% to $3.1 million in 2022, then increased by 1.99% to $3.1 million in 2023, then grew by 2.02% to $3.2 million in 2024, then rose by 1.98% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Current Leases are $3.3 million (Q4 2025), $3.2 million (Q3 2025), and $3.2 million (Q2 2025).